原发性肝癌患者血清IL-2表达的意义

The Evaluattion of Serum IL-2 Levels in Patients with Primary Hepatocellular Carcinoma

目的:探讨原发性肝癌患者白细胞介素-2(IL-2)表达的意义。方法:采用ELISA法测定不同分期原发性肝癌血清IL-2表达水平,并与同期体检并合格的健康男性作对照。结果:原发性肝癌IL-2为2.85±0.79 ng/mL,健康对照组为6.97±1.58 ng/mL,2者比较有显著性差异(P<0.05)。IL-2表达水平在原发性肝癌伴有远处转移与无远处转移患者中分别为2.46±1.25 ng/mL、5.51±2.14 ng/mL,2者比较有显著性差异(P<0.05)。IL-2表达水平在肝癌肿块直径>5 cm患者为1.96±0.67 ng/mL,而在肿块直径<5 cm的患者为4.89±1.69 ng/mL,2者比较有显著性差异(P<0.05)。结论:原发性肝癌患者血清IL-2表达水平显著降低,并与肿瘤的大小及有无远处转移密切相关。

Objective： To evaluate the levels of serum IL- 2 ＇in patients with primary hepatocellular carcinoma and its clinical significance. Methods： Serum IL - 2 concentrations were measured by ELISA. The association between serum IL -2 levels and clinic pathological features were analyzed. Results：serum IL -2 levels in patients with primary hepatocellular carcinoma were significantly lower than those in healthy persons （P 〈 0.05）. The expression levels of IL - 2 in patients with distant metastasis and without distant metastasis were 2.46 ±1.25 ng/mL and 5.51 ±2.14 ng/mL, respeetively（P 〈0.05）. The serum expression levels of IL - 2 in patients with tumor size bigger than 5 cm and with tumor size smaller than 5 em in diameter were 1.96 ± 0.67 ng/mL and 4.89 ±1.69 ng/mL, respectively. Conclusion： The decreased levels of serum IL - 2 in patients with primary hepatocellular carcinoma are closely correlated to tumor size and clinical staging.